Tirzepatide# Tirzepatide is a 39-amino acid peptide with a C20 fatty diacid side chain that activates two receptors: GIP receptor : Tirzepatide shows approximately 5-fold selectivity for GIP over GLP-1 receptors, representing a GIP-dominant dual agonist GLP-1 receptor : Provides complementary glucose-lowering and appetite-suppressing effects The GIP receptor engagement is a key differentiator from pure GLP-1 agonists like semaglutide
These are not minor improvements
AOD-9604 will not produce the 20-50 pound transformations that GLP-1 agonists produce
Factors such as heat, light exposure, moisture, improper reconstitution, or rough handling can compromise the integrity of this complex 39-amino-acid triple agonist molecule without overt visual indicators
The phase 2 trial showed 17.1% average body weight reduction at 48 weeks with the 4mg dose
The experience that Ive had with my patients points me to think there is something more physiological, neurobiological going on that the medication addresses. People who binge as a coping mechanism may also find that anxiety gets worse once appetite is suppressed
